Article
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Value in health regional issues - 1 May 2020
Shafie Asrul Akmal, Abu Hassan Muhammad Radzi, Ong Siew Chin, Virabhak Suchin, Gonzalez Yuri Sanchez
Abstract excerpt
OBJECTIVES: The combination of pegylated-interferon and ribavirin (PegIFN+RBV) is currently the gold standard in treating chronic hepatitis C virus (HCV) patients in Malaysia and is reimbursed by the Malaysian authorities. This analysis evaluated the cost-effectiveness (CE) of the ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (OBT/PTV/r+DSB±RBV) regimen as compared with the PegIFN+RBV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.